Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Citi says Divi's Labs 'top pick' among Indian pharma sector; stock jumps

** Divi's Laboratories  DIVI.NS  shares up 3.8%, top gainer in
Nifty pharma index  .NIPHARM  which is up 2.6%
    ** Citi says DIVI remains its top pick in Indian
pharmaceutical sector
    ** Brokerage expects DIVI's key drug Entresto active pharma
ingredient (API) sales to rise vs street expectations of decline
    ** DIVI likely to supply Entresto API to generics
manufacturers as well after patent expires - Citi
    ** DIVI snaps three-day losing streak
    ** Citi has "buy" rating on stock, with PT at 6,850 rupees
    ** Analysts on average rate stock a "hold", with median PT
at 5,285 rupees, per LSEG data 
    ** DIVI up ~ 59% YTD vs ~32% gains in pharma index 

(Reporting by Sethuraman NR)
((Sethuraman.NR@thomsonreuters.com; (+91 9945291420); Reuters
Messaging: nallur.sethuraman.thomsonreuters.com@reuters.net))

Recent news on Divi's Laboratories

See all news